Defining intended use is one of the most important steps in validating AI and SaaS tools in regulated pharma and biotech environments. The intended use statement establishes validation scope, testing strategy, risk classification, supplier oversight expectations, and procedural controls. For AI systems, this is often more difficult than traditional software because operational usage can evolve

Turning Supplier Audit Files into Actionable Insights for a Mid-Size Biotech Introduction A mid-size biotech organization with approximately 600 employees and a single GMP manufacturing site faced a common challenge: hundreds of supplier audit reports, self-assessment questionnaires, and CAPA summaries stored across multiple folders, but no easy way to extract trends or prioritize risks. The

Scenario & Background A mid-sized biotech company developing a novel oncology cell therapy was running multiple Phase II trials across different sites. The company’s internal safety team was overwhelmed by the volume of adverse event (AE) reports and needed support in: However, the client did not want a new IT platform or continuous system integration.

In the biotech industry, the integrity of documentation is just as critical as the product itself. Master Batch Records (MBRs) guide the execution of production steps, while Standard Operating Procedures (SOPs) define how those steps should be performed and documented. These two document types are deeply interconnected, and any misalignment between them can lead to

Scenario: A Biotech Company Analyzing 500+ Deviations to Uncover Trends and Gain Cross-Departmental Clarity A mid-sized biotech company had over 500 deviations logged at a single manufacturing site, spread across multiple departments including Quality, Manufacturing, Engineering, and Supply Chain. The data resided in their existing systems (QMS, Excel exports, reports), and they saw an opportunity